clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia
Cited by National Institute for Health and Care Excellence on
The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.